Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Pediatric Oncology

Standard of Care: Customizing Radiation and Chemotherapy

At a Glance

Modern medulloblastoma treatment combines surgery, radiation, and chemotherapy, tailored to a patient's age and tumor molecular subgroup. Infants often receive high-dose chemotherapy to avoid radiation, while older patients may receive precision proton therapy to minimize side effects.

Modern treatment for medulloblastoma is “multimodal,” meaning it combines surgery, radiation, and chemotherapy to achieve the best possible outcome [1]. Today, the path forward is highly personalized based on your child’s age and their tumor’s molecular subgroup [2][3].

Treatment Strategy by Age

Because a child’s brain develops rapidly, the strategy changes as they grow to protect their cognitive and physical health.

Children Over Age 3

The standard of care for older children is surgery followed by Craniospinal Irradiation (CSI) and chemotherapy [1].

  • Standard Risk: These children typically receive a lower dose of CSI (usually 23.4 Gy) to minimize the impact on memory and learning [4].
  • High Risk: If there is evidence of spread or residual tumor, a higher dose (usually 36 Gy) is used [5].

Infants Under Age 3

The brains of infants and toddlers are extremely sensitive to radiation. To avoid permanent neurological damage, doctors often use a strategy to avoid or delay radiation [6]. This typically involves High-Dose Chemotherapy with Autologous Stem Cell Rescue (ASCR) [7]. In this process, a child’s own healthy stem cells are collected and then returned to them to help their body recover from very intensive chemotherapy [8][9].

Adults

Medulloblastoma is rare in adults, and the SHH subgroup is the most common [10]. While treatment is similar to the pediatric approach (surgery, CSI, and chemo), adults are often managed in specialized neuro-oncology centers that can tailor treatment to their specific needs [11][12].

The Proton Advantage

When radiation is required, Proton Beam Therapy (PBT) is increasingly preferred over traditional photon (X-ray) radiation [13].

  • Dosimetric Advantage: Unlike X-rays, which pass through the entire body, protons stop exactly at the tumor site [14].
  • Protecting Healthy Tissue: This precision helps spare healthy organs like the heart, thyroid, and stomach, reducing the long-term risk of hormone issues, growth limitations, and secondary cancers [15][16].

Personalized and Targeted Therapies

As we understand more about the “molecular fingerprint” of medulloblastoma, new targeted treatments are emerging.

  • WNT De-intensification: Because the WNT subgroup has such an excellent survival rate (over 90%), clinical trials are testing if lower doses of radiation and chemotherapy can maintain these high cure rates while reducing side effects [17][18].
  • SHH Inhibitors: For tumors in the SHH group, targeted drugs like SMO inhibitors (e.g., vismodegib) are being studied to block the specific signaling pathway that drives the cancer [19][20].
  • Emerging Research: New trials are investigating inhibitors that target specific genetic markers like DNA-PK or CDK4/6 to overcome treatment resistance [21][22].

The goal of modern care is a “cure with quality,” ensuring that survivors don’t just overcome cancer but live full, healthy lives [6].

Common questions in this guide

What is the standard treatment for medulloblastoma?
Standard treatment is multimodal, typically combining surgery, craniospinal irradiation (radiation), and chemotherapy. The exact treatment plan is highly personalized based on the patient's age and the tumor's specific molecular subgroup.
How is medulloblastoma treated in infants and toddlers?
Because young brains are very sensitive to radiation, doctors often try to delay or avoid it in children under three. Instead, they typically use high-dose chemotherapy followed by an autologous stem cell rescue to help the body recover.
Why is proton beam therapy used for medulloblastoma?
Proton beam therapy is often preferred because it allows doctors to stop the radiation exactly at the tumor site. This precision helps protect healthy tissues, reducing the risk of long-term side effects like hormone issues and growth limitations.
Are there targeted therapies for medulloblastoma?
Yes, targeted therapies are emerging based on molecular subgroups. For example, SMO inhibitors like vismodegib are being studied for SHH-subgroup tumors, and clinical trials are testing reduced treatment intensity for the WNT subgroup to minimize side effects.
What is craniospinal irradiation (CSI)?
Craniospinal irradiation is a type of radiation therapy directed at the brain and spinal cord. It is a standard treatment for older children and adults with medulloblastoma, with doses carefully tailored to the patient's specific risk level.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the planned dose of craniospinal irradiation (CSI) for my child (e.g., 23.4 Gy or 36 Gy)?
  2. 2.If my child is an infant, can we use high-dose chemotherapy to avoid radiation entirely?
  3. 3.Is proton beam therapy available at this hospital, and if not, can you provide a referral to a proton center?
  4. 4.For an SHH-subgroup tumor, are there any targeted therapy trials (like SMO inhibitors) that we should consider?
  5. 5.For a WNT-subgroup tumor, is my child a candidate for a 'de-intensification' trial to reduce the side effects of treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Advancing medulloblastoma therapy: strategies and survival insights.

    Pan Z, Bao J, Wei S

    Clinical and experimental medicine 2025; (25(1)):119 doi:10.1007/s10238-025-01648-5.

    PMID: 40237916
  2. 2

    Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.

    Kian W, Roisman LC, Goldstein IM, et al.

    JCO precision oncology 2020; (4()) doi:10.1200/PO.19.00264.

    PMID: 32923880
  3. 3

    Medulloblastoma: optimizing care with a multidisciplinary approach.

    Thomas A, Noël G

    Journal of multidisciplinary healthcare 2019; (12()):335-347 doi:10.2147/JMDH.S167808.

    PMID: 31118657
  4. 4

    Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study.

    Fukuoka K, Kurihara J, Shofuda T, et al.

    Acta neuropathologica communications 2023; (11(1)):153 doi:10.1186/s40478-023-01652-4.

    PMID: 37749662
  5. 5

    Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk/metastatic medulloblastoma in a resource-limited setting.

    Gupta T, Sinha S, Chinnaswamy G, et al.

    Pediatric blood & cancer 2021; (68(5)):e28925 doi:10.1002/pbc.28925.

    PMID: 33533557
  6. 6

    Medulloblastoma.

    Millard NE, De Braganca KC

    Journal of child neurology 2016; (31(12)):1341-53 doi:10.1177/0883073815600866.

    PMID: 26336203
  7. 7

    High-dose chemotherapy with autologous stem cell rescue in children under 5 years of age with central nervous system embryonal tumors: results from a prospective cohort in an upper-middle-income country.

    Cappellano AM, Dassi N, Gamba FT, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2026; (42(1)).

    PMID: 42380328
  8. 8

    Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen.

    Baroni LV, Sampor C, Gonzalez A, et al.

    Neuro-oncology 2020; (22(12)):1873-1881 doi:10.1093/neuonc/noaa122.

    PMID: 32413139
  9. 9

    High-Dose Chemotherapy in Children with Newly Diagnosed Medulloblastoma.

    Lafay-Cousin L, Dufour C

    Cancers 2022; (14(3)) doi:10.3390/cancers14030837.

    PMID: 35159104
  10. 10

    Adult Medulloblastoma: Updates on Current Management and Future Perspectives.

    Franceschi E, Giannini C, Furtner J, et al.

    Cancers 2022; (14(15)) doi:10.3390/cancers14153708.

    PMID: 35954372
  11. 11

    Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397).

    Moots PL, O'Neill A, Londer H, et al.

    American journal of clinical oncology 2018; (41(6)):588-594 doi:10.1097/COC.0000000000000326.

    PMID: 27635620
  12. 12

    Adult medulloblastoma in an Australian population.

    Parakh S, Davies A, Westcott K, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; (102()):65-70 doi:10.1016/j.jocn.2022.06.008.

    PMID: 35728397
  13. 13

    Systematic Review and Meta-Analysis of Proton Beam Therapy Versus Photon Radiotherapy for Medulloblastoma: TRP-Medulloblastoma 2025.

    Li Y, Mizumoto M, Oshiro Y, et al.

    Cancers 2025; (17(13)) doi:10.3390/cancers17132191.

    PMID: 40647489
  14. 14

    Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma.

    Vogel J, Lin L, Litzky LA, et al.

    International journal of radiation oncology, biology, physics 2017; (99(2)):427-433 doi:10.1016/j.ijrobp.2017.04.022.

    PMID: 28871993
  15. 15

    Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines.

    Mizumoto M, Fuji H, Miyachi M, et al.

    Cancer treatment reviews 2021; (98()):102209 doi:10.1016/j.ctrv.2021.102209.

    PMID: 33984606
  16. 16

    Estimated Risk of Radiation-Induced Cancer after Thymoma Treatments with Proton- or X-ray Beams.

    Lideståhl A, Johansson G, Siegbahn A, Lind PA

    Cancers 2021; (13(20)) doi:10.3390/cancers13205153.

    PMID: 34680302
  17. 17

    Childhood medulloblastoma.

    Massimino M, Biassoni V, Gandola L, et al.

    Critical reviews in oncology/hematology 2016; (105()):35-51.

    PMID: 27375228
  18. 18

    Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients.

    Gottardo NG, Gajjar A

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(24)):4996-4998 doi:10.1158/1078-0432.CCR-23-2331.

    PMID: 37823794
  19. 19

    Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.

    Yao YL, Wang YX, Yang FC, et al.

    CNS neuroscience & therapeutics 2022; (28(7)):1033-1044 doi:10.1111/cns.13835.

    PMID: 35419951
  20. 20

    Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.

    Rimkus TK, Carpenter RL, Qasem S, et al.

    Cancers 2016; (8(2)).

    PMID: 26891329
  21. 21

    Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastoma.

    DeCarlo A, MacLeod G, Fernandes da Silva C, et al.

    Cell reports. Medicine 2025; (6(7)):102202 doi:10.1016/j.xcrm.2025.102202.

    PMID: 40562042
  22. 22

    Spatial transcriptomic analysis of Sonic hedgehog medulloblastoma identifies that the loss of heterogeneity and promotion of differentiation underlies the response to CDK4/6 inhibition.

    Vo T, Balderson B, Jones K, et al.

    Genome medicine 2023; (15(1)):29 doi:10.1186/s13073-023-01185-4.

    PMID: 37127652

This page provides informational content about medulloblastoma treatment strategies. Always consult your pediatric neuro-oncologist or specialized healthcare provider for personalized medical advice regarding your child's specific care plan.

Get notified when new evidence is published on Medulloblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.